Skip to main content
Terug
Watch Compare

CASI Pharmaceuticals, Inc.

Datakwaliteit: 100%
CASIF
OTC Manufacturing Chemicals
€ 0,12
▼ € 0,00 (-0,74%)
Marktkapitalisatie: 2,50 M
Prijs
€ 0,12
Marktkapitalisatie
2,50 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Debt/Equity of 10,21 — high leverage
Negative free cash flow of -29,45 M
Capital efficient — spends only 0,78% of revenue on capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)-15,77%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-301,80%
Onder sectorgemiddelde (-53,34%)
ROIC-82,63%
Net Margin-137,57%
Op. Margin-138,84%

Veiligheid

Debt / Equity
10,21
Boven sectorgemiddelde (0,31)
Current Ratio1,09
Interest CoverageN/A

Waardering

PE (TTM)
-0,06
Boven sectorgemiddelde (-1,47)
P/B Ratio1,35
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,1 -1,5
P/B 1,4 1,6
ROE % -301,8 -53,3
Net Margin % -137,6 -41,5
Rev Growth 5Y % — 1,8
D/E 10,2 0,3

Koersdoel Analisten

1 analist
Hold
Huidig
€ 0,12
+3205.8%
Koersdoel
€ 4,00
€ 4,00
€ 4,00
€ 4,00
Vooruitzicht
Forward WPA -€ 1,41
Omzet Sch. 0,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2026 -€ 1,41
-€ 1,41 – -€ 1,41
 0,0 1

Winstverassingen

Laatste 3 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q32025 -€ 0,40 -€ 0,67 -67,5%
Q22025 -€ 0,47 -€ 0,86 -83,0%
Q12025 -€ 0,61 -€ 0,69 -13,1%

All Fundamental Metrics
Growth
Revenue Growth (1Y) -15,77% Revenue Growth (3Y) -18,64%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 28,54 M Net Income (TTM) -39,26 M
ROE -301,80% ROA -60,89%
Gross Margin 39,06% Operating Margin -138,84%
Net Margin -137,57% Free Cash Flow (TTM) -29,45 M
ROIC -82,63% FCF Growth (3Y) N/A
Safety
Debt / Equity 10,21 Current Ratio 1,09
Interest Coverage N/A Asset Turnover 0,44
Working Capital 3,12 M Tangible Book Value 1,61 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,06 Forward P/E N/A
P/B Ratio 1,35 P/S Ratio 0,09
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -1175,61%
Market Cap 2,50 M Enterprise Value 7,93 M
Per Share
EPS (Diluted TTM) -2,56 Revenue / Share 1,39
FCF / Share -1,43 OCF / Share -1,42
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,78% FCF Conversion 75,01%
SBC-Adj. FCF -30,75 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022
Revenue 28,54 M 33,88 M 43,11 M
Net Income -39,26 M -26,96 M -41,01 M
EPS (Diluted) -2,56 -2,02 -3,01
Gross Profit 11,15 M 20,05 M 27,28 M
Operating Income -39,62 M -25,08 M -34,03 M
EBITDA — — —
R&D Expenses 8,92 M — —
SG&A Expenses — — —
D&A 1,30 M 2,50 M 1,20 M
Interest Expense — 614.000,0 0,0
Income Tax 0,0 -81.000,0 1,98 M

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022
Total Assets 53,67 M 75,27 M 96,23 M
Total Liabilities 51,82 M 51,10 M 29,30 M
Shareholders' Equity 1,85 M 24,17 M 44,57 M
Total Debt 18,90 M 18,90 M —
Cash & Equivalents 13,47 M 17,08 M 47,11 M
Current Assets 39,58 M 59,34 M 73,42 M
Current Liabilities 36,45 M 16,73 M 17,01 M